Van den Eynde B J, van der Bruggen P
Ludwig Institute for Cancer Research, Brussels, Belgium.
Curr Opin Immunol. 1997 Oct;9(5):684-93. doi: 10.1016/s0952-7915(97)80050-7.
T cell defined antigens have now been characterized in a large variety of tumor types, in both mice and humans. An increasing number of these antigens appear to result from tumor-specific mutations, and some of these mutations may be implicated in oncogenesis. The priority is now to demonstrate that immunization against some of these antigens is clinically valuable for antitumor therapy, and the first results of clinical pilot studies are now emerging.
现已在多种肿瘤类型中,对小鼠和人类的T细胞定义抗原进行了表征。越来越多的这些抗原似乎源于肿瘤特异性突变,其中一些突变可能与肿瘤发生有关。目前的首要任务是证明针对其中一些抗原进行免疫在抗肿瘤治疗中具有临床价值,临床试点研究的首批结果现已显现。